Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
116.6 USD | -1.44% | -10.80% | -16.27% |
Apr. 16 | ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca | |
Apr. 16 | Baptista Research Downgrades Illumina to Hold From Buy, Adjusts PT to $149.60 From $145 | MT |
Evolution of the average Target Price on Illumina, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Illumina, Inc.
Baptista Research | |
Leerink Partners | |
RBC Capital Markets | |
OTR Global | |
UBS | |
TD Cowen | |
Barclays | |
Citigroup | |
Stifel Nicolaus | |
Baird | |
Scotiabank | |
Stephens Inc. | |
BofA Securities | |
Canaccord Genuity | |
Bernstein | |
Piper Sandler | |
HSBC | |
JPMorgan Chase | |
Evercore ISI | |
Credit Suisse | |
SVB Securities LLC | |
Argus | |
Morgan Stanley | |
Cowen | |
SVB Leerink | |
BTIG | |
Wells Fargo Securities | |
Atlantic Equities |
EPS Revisions
- Stock Market
- Equities
- ILMN Stock
- Consensus Illumina, Inc.